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Osteoarthritis (OA) is a multifactorial disease and nutrition is a modifiable factor that may contribute 
to disease onset or progression.  A detailed understanding of mechanisms through which diet-
derived bioactive molecules function and interact in OA is needed. 
We profiled 96 diet-derived, mainly plant-based bioactives using an in vitro model in chondrocytes, 
selecting four candidates for further study.  We aimed to determine synergistic interactions between 
bioactives that affected the expression of key genes in OA.   
Selected bioactives, sulforaphane, apigenin, isoliquiritigenin and luteolin, inhibited one or more 
interleukin-1-induced metalloproteinases implicated in OA (MMP1, MMP13, ADAMTS4, ADAMTS5). 
Isoliquiritigenin and luteolin showed reactive oxygen species scavenging activity in chondrocytes 
whereas sulforaphane had no effect and apigenin showed only a weak trend.  Sulforaphane inhibited 
the IL-1/NFκB and Wnt3a/TCF/Lef pathways and increased TGFβ/Smad2/3 and BMP6/Smad1/5/8 
signalling.  Apigenin showed potent inhibition of the IL-1/NFκB and TGFβ/Smad2/3 pathways, 
whereas luteolin showed only weak inhibition of the IL-1/NFκB pathway. All four bioactives inhibited 
cytokine-induced aggrecan loss from cartilage tissue explants. The combination of sulforaphane and 
isoliquiritigenin was synergistic for inhibiting MMP13 gene expression in chondrocytes. 
We conclude that dietary-derived bioactives may be important modulators of cartilage homeostasis 
and synergistic relationships between bioactives may have an anti-inflammatory and 
chondroprotective role. 
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Introduction 
Osteoarthritis (OA) is a global problem and a leading cause of disability1,2.  OA is the most common 
type of arthritis affecting 13.2% of males and 19.8% of females in the UK 3. There are no effective 
disease-modifying drugs for OA, with pharmacological treatment restricted to pain relief.  Treatment 
of chronic conditions such as osteoarthritis (OA) is further complicated by co-morbidities as the risk 
escalates with age 4.  The importance of the health, economic and societal issues surrounding OA 
was acknowledged by the General Assembly of the United Nations and World Health Organisation 5,6 
OA is a disease affecting the entire di-arthrodial joint where degeneration of the articular cartilage, 
changes in the underlying (subchondral) bone and synovial inflammation are typically seen.  This 
disease is a major cause of disability, results in a loss of mobility in the affected joint and unmanaged 
pain symptoms detrimental to quality of life 7.  Metalloproteinases commonly linked to the 
destruction of articular cartilage are the collagenase MMP-13 and aggrecanases ADAMTS-4 and 
ADAMST-5 8,9. 
A change in the typical approach to chronic disease management may benefit patients 10.  The 
consequence for conditions of slow progression such as osteoarthritis is a late presentation of 
symptoms, when joint damage has already occurred.  This may in part account for the lack of 
effective disease-modifying interventions for OA.  With age as a primary risk factor for OA, the entire 
population can be considered as ‘at risk’ for disease.  Dietary intervention as a strategy to reduce risk 
at the population level provides a low risk option with potentially wide-reaching benefits 11.  
Available epidemiological data suggest that dietary constituents, specifically carotenoids, n3-
polyunsaturated fatty acids (PUFA), vitamin K and allium intake are associated with a reduction in 
the progression of OA in man12.  A number of other plant-derived phytochemicals outside of 
nutrients themselves, have been proposed to have benefits on joint health and OA e.g. 13,14 but 
translation to man has been slow.  Detailed molecular studies both in vitro and in vivo are required 
in order to establish modes of action, which are different from traditional single target 
pharmaceuticals, and to optimise clinical trial design in order to gain optimal evidence of efficacy in 
both disease treatment and prevention.   
Previously, our research in this area has focused on sulforaphane, an isothiocyanate derived from 
the glucosinolate precursor glucoraphanin, which is abundant in cruciferous vegetables, particularly 
broccoli.  It is widely known for its cytoprotective, anti-inflammatory, anti-microbial and anti-
tumourigenic activities.  There are a number of reports on the potential for SFN in OA describing 
protection of chondrocytes from cell death, repression of catabolic metalloproteases, intra-articular 
administration using microspheres to protect cartilage, protection of subchondral bone and cartilage 
protection in mouse models of OA 15-19. 
We sought to extend knowledge in this area by screening a library of diet-derived bioactives for 
inhibition of either basal or interleukin-1-induced expression of matrix metalloproteinase-13 
(MMP13) in two chondrocyte-like cell lines as a surrogate for chondroprotection.  The top ‘hits’ from 
this screen were further tested in primary human articular chondrocytes which led us to focus on 
four bioactives for possible synergism (sulforaphane (SFN), apigenin (API), isoliquiritigenin (ISO) and 
luteolin (LUT)).  These compounds were then examined for mechanism of action but also their 
interaction. 
Flavonoids are polyphenolic compounds common to a wide range of plant foods.  Flavones are a 
flavonoid sub-class to which apigenin and luteolin belong.  Apigenin is found abundantly in bell 
peppers, garlic, belimbi fruit, guava, celery, parsley and chamomile.  Sources of luteolin are bird’s 
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eye chilli, onions, carrots and olive oil 20,21.  Luteolin is reported to inhibit aggrecanases ADAMTS4 
and ADAMTS5 in ATDC5 cells and murine cartilage explants 22 and apigenin is a hyaluronidase 
inhibitor as demonstrated by in vitro turbidity assay and in bovine cartilage explants 23,24, and is 
reported to inhibit metalloproteinase expression in primary rat articular chondrocytes and the 
human SW1353 chondrosarcoma cell line 25,26. 
Isoliquiritigenin is also a flavonoid found in liquorice root, though has a chalcone structure.  
Chalcone derivatives are shown to have wide ranging bioactivities such as anti-inflammatory, anti-
oxidant, anti-microbial activity 27.  Isoliquiritigenin is reported to protect subchondral bone in a 
mouse model of OA 28, repress interleukin-1-induced matrix metalloproteinases in rat primary 
chondrocytes 29, protect cartilage in the anterior cruciate ligament transection (ACLT) mouse model 
of OA,  and inhibit the inflammatory nuclear factor kappa B (NFκB) pathway in a rat model of 
intracerebral haemorrhage and ATDC5 cells 30,31, also affecting the NLRP3 inflammasome and 
inducing NRF2 signalling 30. 
Results 
Key matrix metalloproteinases in osteoarthritis:  diet-derived bioactives inhibit gene expression. 
In order to identify compounds which were potentially chondroprotective, ninety six diet-derived 
bioactives were screened at 10 μM against basal and IL-1-induced MMP13 expression (measured by 
RT-qPCR) in SW1353 human chondrosarcoma and C28/I2 immortalised human costal chondrocytes.  
Each screen was performed once n=1, with three replicates of each condition, with the 10 μM dose 
chosen pragmatically in order to reveal activity. 
The heat-map (Supplementary data S1) shows distinct areas of high and low MMP13 expression for 
IL-1 treated SW1353 cells. Two clades (highlighted) of low MMP13 expression across the two cell 
lines were noted to contain apigenin, isoliquiritigenin and luteolin.  
From these initial screens, ten bioactives were selected and with sulforaphane (identified in our 
previous research16) they were tested for inhibition of MMP13 expression, but also other cartilage 
matrix-degrading proteases MMP1, ADAMTS4 and ADAMTS5.  Human primary chondrocytes (HACs) 
isolated from three separate patients n=3, were treated with 10 µM genistin, luteolin, polydatin, 
curcumin, apigenin, myricetin, isoliquiritigenin, ursolic acid, epigallocatechin gallate, naringin or 
sulforaphane in triplicate for 6 hours, or pre-treated with 10 µM of each bioactive for 30 mins then 
5ng/ml IL-1 for 6 hours. Levels of protease gene expression are shown in Table 1 (IL-1-induced) and 
Table 2 (basal).  
IL1-induced MMP1, MMP13, ADAMTS4 and ADAMTS5 mRNA expression was consistently decreased 
by luteolin but did not reach statistical significance. Apigenin significantly decreased IL-1-induced 
MMP13, ADAMTS4 and ADAMTS5 expression (mean fold change and 95% CI: 0.18 (0.09 to 1.55), 
p=0.005, 0.11 (0.20 to 1.58), p=0.0001 and 0.22 (-0.06 to 1.62), p=0.018 respectively). 
Isoliquiritigenin significantly decreased the expression of IL-1-induced MMP13, ADAMTS4 and 
ADAMTS5 (mean fold change and 95% CI: 0.14 (0.14 to 1.59), p=0.0005, 0.08 (0.15 to 1.69), 
p=0.0001, and 0.11 (0.05 to 1.73), p=0.001 respectively).  Sulforaphane significantly decreased IL-1-
induced expression of MMP13 and ADAMTS4 (mean fold change and 95% CI: 0.12 (0.15 to 1.61), 
p=0.001, 0.03 (0.28 to 1.66), p=0.0001), while showing a trend to decreasing both IL-1-induced 
MMP1 and ADAMTS5 (Table 1).  Ursolic acid increased basal MMP1 expression mean fold change 
4.34 (95% CI: -5.87 to -0.82 p=0.004) and sulforaphane inhibited basal ADAMTS5 expression mean 
fold change 0.25 (95% CI: 0.23 to 1.27, p=0.001) (Table 2).  Three bioactives apigenin (API), 
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isoliquiritigenin (ISO) and luteolin (LUT) were taken forwards, along with sulforaphane (SFN), as 
having activity regulating the expression of four key genes relevant to OA in HACs.   
We established a dose response for each bioactive against IL-1-induced MMP13 expression in HACs 
using three separate patient cell isolates n=3, each in triplicate conditions (Figure 1).  SFN reached 
significance at 12 µM and 24 µM mean fold change and 95% CI: 0.11 (0.53 to 1.26) p=0.0001, and 
0.05 (0.57 to 1.33) p=0.0001 respectively (Figure 1a). API reached significance at 8 µM mean fold 
change and 95%CI: 0.35 (0.36 to 0.95) p=0.037, 16 µM 0.07 (0.65 to 1.22) p=0.0001 and 32 µM 0.03 
(0.68 to 1.25) p=0.0001 (Figure 1b). ISO was significant at 10 µM mean fold change and 95%CI: 0.30 
(0.35 to 1.06) p=0.002 and 20 µM 0.06 (0.59 to 1.30) p=0.0001 (Figure 1c).  LUT was significant at 20 
µM mean fold change and 95%CI: 0.11 (0.60 to 1.17) p=0.0001 and 40 µM 0.04 (0.67 to 1.25) 
p=0.0001 (Figure 1d).          
Hence, a wide screen of dietary-derived bioactives led us to focus on a subset of 10 compounds with 
further analyses highlighting 4 compounds, which dose-dependently inhibit IL-1-induced MMP13 
expression in primary human articular chondrocytes.   
 
Bioactives affect reactive oxygen species (ROS) in primary human chondrocytes 
In order to investigate potential mechanism of action, direct antioxidant activity of the bioactives 
was measured in primary human articular chondrocytes (three separate patient cell isolates n=3, 
each in triplicate).  Primary chondrocytes were pre-treated for 30 minutes with the bioactives and 
then 100 µM tert-butyl hydrogen peroxide (tBHP) was added to induce cellular reactive oxygen 
species (ROS).  
ISO and LUT showed a dose dependent inhibition of tBHP-induced ROS that was statistically 
significant (Figure 2). ISO inhibited ROS production: (3 µM mean fold change and 95% CI: 0.48 (0.26 
to 0.78), p=0.030, 6 µM 0.27 (0.47 to 0.99), p= 0.0005) and 12 µM 0.12 (0.62 to 1.14), p= 0.0001 
(Figure 2c).  LUT inhibited ROS production: (1.5 µM mean fold change and 95% CI: 0.33 (0.41 to 
0.94), p=0.0035, 3 µM 0.10 (0.64 to 1.16), p=0.0001, 6 µM 0.04 (0.70 to 1.22), p=0.0001 and 12 µM 
0.03 (0.71 to 1.24), p=0.0001) (Figure 2d).  No effect was seen for SFN or API (Figure 2a & 2b).  
This showed that both ISO and LUT exert a direct antioxidant effect in chondrocytes, in contrast to 
SFN and API. 
 
Transcriptional signalling pathway analysis 
A number of signalling pathways play a role in cartilage homeostasis and OA.  Luciferase reporters 
for IL-1/nuclear factor-kappa B, TGF-β/Smad2/3, Wnt3A/TCF/Lef, and BMP6/Smad1/5/8 signalling 
pathways were used to measure transcriptional activity in response to SFN, API, ISO and LUT 
treatment (Figure 3). Data are from a minimum of three independent experiments (n=3) each 
performed in triplicate. 
SFN dose dependently inhibited IL-1-induced NFκB signalling reaching significance at 12 µM mean 
fold change and 95% CI: 0.11 (0.8 to 1.7), p=0.003 (Figure 3a) and Wnt3A/TCF/Lef signalling (not 
significant) (Figure 3d). SFN showed trends of increasing TGF-β-induced Smad2/3 and BMP6-induced 
Smad1/5/8 signalling (not significant) (Figure 3b & 3c). 
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API strongly inhibited IL-1/NFκB (1.5-12 µM mean fold change and 95%CI: 0.22 (0.30 to 1.26), 
p=0.009, 3 µM 0.09 (0.43 to 1.40), p=0.0001, 6 µM 0.04 (0.48 to 1.44), p=0.0001, 12 µM 0.03 (0.45 to 
1.49), p=0.0001) (Figure 3e) and TGF-β/Smad2/3 signalling at 1.5-12 µM (1.5 µM mean fold change 
and 95% CI: 0.06 (0.22 to 1.67), p=0.002, 3 µM  0.02 (0.26 to 1.70), p=0.0008, 6 µM  0.01 (0.27 to 
1.71) p=0.0001, 12 µM  0.03 (0.19 to 1.76), p=0.001) (Figure 3f).  In contrast API had no effect on 
BMP6/Smad1/5/8 (Figure 3g) and decreased Wnt3A/TCF/Lef activity weakly in a dose dependent 
manner (not significant) (Figure 3h).  
We observed a small decrease in BMP6-induced Smad1/5/8 signalling at 12 µM (not significant) with 
ISO treatment (Figure 3k) but no effect on the IL-1/NFκB, TGF-β/Smad2/3 or Wnt3A/TCF/Lef 
reporters (Figure 3i, 3j & 3l). 
LUT showed a weak dose dependent inhibition of IL-1/NFκB signalling (not significant) (Figure 3m) 
and small decreases at the high concentrations for TGF-β/Smad2/3 (Figure 3n), BMP6/Smad1/5/8 
(Figure 3o) and Wnt3A/TCF/Lef (Figure 3p) reporters (not significant). 
Thus, SFN and API both inhibit NFκB signalling, API also inhibits Smad2/3 signalling.  SFN also shows 
weak induction of Smad2/3 and Smad1/5/8 signalling and repression of canonical Wnt signalling.  
There was minimal impact of the four compounds on other signalling pathways tested. 
 
Bioactives reduce cartilage tissue degradation in vitro 
In order to examine the impact of bioactivity on cartilage homeostasis, bovine nasal cartilage 
explants were induced to degrade using inflammatory cytokines IL-1 and OSM in three independent 
experiments (n=3) each performed in triplicate.  Cartilage was treated with 0-24 µM SFN, API, ISO or 
LUT ± IL-1 and OSM and the degradation product of aggrecan (glycosaminoglycan) was measured 
using 1,9-dimethyl-methylene blue assay (Figure 4).  All four bioactives showed dose-dependent 
patterns inhibiting cartilage degradation: IL1/OSM treatment mean % GAG loss and 95% CI: 57.74 
(41.1 to 61.11).  SFN (24 µM mean % loss and 95% CI: 28.13 (12.06 to 47.16), p=0.0019) and 
significant linear trend (slope = -0.07, p=0.0009, r2 = 0.78) (Figure 4a). API (24 µM mean % loss and 
95% CI: 29.45 (5.99 to 50.6), p=0.022) with significant linear trend (slope = -0.08, p=0.0043, r2 = 0.90) 
(Figure 4b).  ISO (24 µM mean % loss and 95% CI:  40.37 (1.40 to 33.34), p=0.049) and significant 
linear trend (slope = -0.04, p=0.013, r2 = 0.88) (Figure 4c).  Similarly, LUT (24 µM mean % loss and 
95% CI: 32.25 (-5.96 to 56.94), p=0.080), and showed a significant linear trend (slope = -0.07, 
p=0.022, r2 = 0.64) (Figure 4d). 
All compounds show a statistically significant dose-response (i.e significant decrease across the dose 
range even though individual lower concentrations are not significant on their own).  SFN, API and 
ISO show statistical significance in preventing IL1/OSM-induced GAG release from cartilage explants 
at the highest dose tested.  
 
Kinase signalling pathway analysis 
It is likely that compounds alter intracellular kinase signalling, therefore we used kinase arrays to 
identify potential regulation of this in response to IL-1 stimulation (5ng/ml, 10 mins) by SFN or ISO 
(10 µM) in human primary chondrocytes.  SFN inhibited IL-1 phosphorylation of Akt1/2/3 (s473), c-
jun, CREB, ERK1/2, PRAS40, WNK1 (all >25% decrease).  ISO inhibited Akt1/2/3 (s473), β-catenin, 
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EGF-R (>25% decrease).  SFN reduced basal levels of phosphorylation (>50%) compared to control of 
c-jun, CREB, ERK1/2, HSP27, JNK1/2/3, p27 and p38α n=1 (Supplementary data S2). 
Bioactive synergism for inhibition of MMP13 expression in primary chondrocytes 
Since foods are rarely eaten alone, the synergism between compounds with respect to IL1-induced 
MMP13 expression was determined.  All synergy experiments used cell isolates from at least three 
separate patients n=3, each performed in duplicate. The dose-effect relationship parameters of each 
single bioactive SFN, API, ISO and LUT against IL1-induced MMP13 mRNA expression in HACs were 
determined.  The rank order of potency based on the IC50 values were: ISO>SFN>LUT>API in HACs 
(Table 3). 
The combination index (CI) values of bioactive combinations against IL1-induced MMP13 mRNA 
expression in HACs was measured.  Combination ratios were based on IC50 values rather than 
absolute concentrations. Each component had the equipotent combination ratio of: SFN:API:ISO:LUT 
(S:A:I:L) = 0.75:1:0.625:1.25 µM.  Synergism was only seen in the SFN/ISO (SI) combination (mean CI: 
0.724).  Nearly additive combinations were SA (mean CI: 1.02) and AI (mean CI: 1.06) where SA≥AI.  
All three (and four) bioactive combinations were antagonistic. Rank order for antagonism was 
SAIL≥IL≥LSA≥ILS≥AIL≥SL>SAI>AL (Table 4).  Note assigned symbols for the combination indices are 
taken from Chou 32. 
The dose reduction index (DRI) values and relationship to CI values in synergistic combinations were 
determined (Table 5). The two-bioactive combination SFN + ISO show a robust dose reduction from 
ED50 to ED95. This favourable dose reduction was also seen for SFN +API at ED50 to ED75 and API + ISO 
at ED90 to ED95 even though the average unweighted CI values suggest a nearly additive effect (Table 
4). 
A polygonogram summary of two-bioactive combination interactions, for the four bioactives is 
shown (Supplementary data S3).  The combination of SFN and ISO show synergistic activity for 
reducing IL-1 induced MMP13 expression in primary chondrocytes at each effect level.  The average 
combination indices for SFN/API and API/ISO were ‘nearly additive’ however, it is noted that the 
SFN/API combination shows slight to moderate synergism at lower effect levels.   
 
SFN/ISO combination regulates the expression of other key genes in OA. 
In order to investigate the potential of the SFN/ISO combination to interact synergistically to 
regulate other relevant genes, we used RT-qPCR to measure the expression of proteases ADAMTS4, 
ADAMTS5, the Nrf2-induced indirect antioxidant HO-1, and the early NFκB response gene and 
regulator A20.  We used the synergism sample set at equipotent IC50 ratios of 0.75:0.625 µM where 
n=3 (figure 5).   
IL-1-induced ADAMTS4 was inhibited by SFN and ISO singly (not significant) and in combination (SI 
(1.5:1.25 µM) mean fold change 1.27 (95% CI: -1.39 to 0.84), p=0.99), (SI (3:2.5 µM) mean fold 
change 0.16 (95% CI: -0.27 to 1.96), p=0.014), (SI (6:5 µM) mean fold change 0.005 (95% CI -0.12 to 
2.11), p=0.034) (Figure 5a). 
IL-1-induced ADAMTS5 was inhibited by SFN and ISO singly (not significant) and in combination (SI 
(1.5:1.25 µM) mean fold change 0.57 (95% CI: -0.26 to 1.40), p=0.73), (SI (3:2.5 µM) mean fold 
change 0.71 (95% CI: -0.12 to 1.54), p=0.007), (SI (6:5 µM) mean fold change 0.09 (95% CI: 0.08 to 
1.74), p=0.0001) (Figure 5b). 
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HO-1 was induced by SFN singly and in combination with ISO compared to control (SFN 1.5 µM mean 
fold change 6.59 (95% CI: -16.31 to 7.58), p=0.025), (3 µM mean fold change 7.44 (95% CI: -17.17 to 
6.72), p=0.022), (6 µM mean fold change 8.96 (95% CI: -18.69 to 5.20), p= 0.012).  ISO alone did not 
induce HO-1 expression.  In combination, (SI (1.5:1.25 µM) mean fold change 13.74 (95% CI -23.47 to 
0.42), p=0.0018), (SI (3:2.5 µM) mean fold change 22.5 (95% CI -32.22 to -8.33), p=0.0001), (SI (6:5 
µM) mean fold change 23.86 (95% CI: -33.59 to -9.70), p=0.0001) (Figure 5c). 
IL-1-induced A20 was inhibited by SFN singly (not significant) and in combination with ISO (SI (1.5:2.5 
µM) mean fold change 1.02 (95% CI: -1.68 to 1.63), p=0.997), (SI (3:2.5 µM) mean fold change 0.23 
(95% CI: -0.89 to 2.42), p=0.16, (SI (6:5 µM) mean fold change 0.04 (95% CI: -0.69 to 2.62), p=0.004) 
(Figure 5d). 
Whilst mathematical synergism for these genes wasn’t determined as for MMP13 above, the 
combination of SFN and ISO together was clearly more effective that either compound alone, 
confirming the utility of the approach. 
 
Discussion 
A strategy to prevent or treat OA using dietary modification, supplementation or the development 
of functional foods is clearly attractive.  It also has wide public health implications particularly in a 
chronic disease which is increasing in prevalence with no disease-modifying treatments currently 
available.  There is a need to understand the mechanism by which diet-derived bioactives can impact 
upon the joint, both in vitro and in vivo.  This is vital for the design of appropriate intervention trials 
and therefore the translation to treatment in man.    
Our strategy was to screen diet-derived compounds for their ability to inhibit either basal or IL1-
induced MMP13 expression since this identified SFN, which was then shown to be 
chondroprotective in animal models of OA16 .   Further we hypothesised that if bioactives regulate 
gene expression through differing mechanisms, then they are more likely to be synergistic.  Of the 
96 bioactives in our initial screen for expression of key OA metalloproteinase genes, the four most 
efficacious compounds were SFN, API, ISO and LUT.  
The effect of SFN on metalloproteinase expression and cartilage degradation was in line with earlier 
work 16,33,34 and unsurprisingly, had no direct effect on ROS production since it is well documented by 
others that SFN is an indirect antioxidant35.  SFN affected each of the four cytokine-stimulated 
pathways; IL-1, TGFβ, BMP6 and Wnt3A with differing efficacy.  Of the four pathways analysed, SFN 
interacted most strongly with the IL-1/NFκB pathway, likely in part as a function of SFN’s known 
indirect antioxidant and anti-inflammatory activities, which we have reported previously16.  SFN also 
inhibited Wnt3a canonical signalling, an observation seen previously in breast cancer stem cells36 but 
diverged to enhance both TGFβ/Smad signalling, (which is reported similarly in colorectal cancer 
cells though not in a murine model of muscle fibrosis37,38), and BMP6 signalling.  Moreover, 
BMP6/Smad1/5/8 pathway is reported to induce HO-1 expression 39,40 and so SFN could be viewed 
overall as a dietary modulator of cartilage homeostasis.  This is reinforced by its efficacy in animal 
models of OA 16,17,19.   Since SFN is a well-known activator of the NRF2 signalling pathway 41 and 
though not measured here, this may be a significant contributing mechanism of action. 
Our data support previous studies where API inhibited IL-1-induced metalloproteinase expression 
25,26, and is reflected by the decrease in glycosaminoglycan loss also seen by Lim et al 26 in rabbit 
articular cartilage.  API showed remarkably strong and targeted activity for inhibiting IL-1/NFκB and 
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TGF-β/Smad2/3 signalling pathways while having no effect on BMP6/Smad1/5/8 signalling or only a 
weak inhibitory effect on the Wnt3A/TCF/Lef pathway. Inhibition of NFκB signalling by API agrees 
with some earlier studies 42,43 (though not Lim et al 26), as does the inhibition of TGFβ/Smad 
signalling in prostate cancer cell lines 44.  Conversely, Zhang et al demonstrate apigenin activation of 
the TGFβ/Smad pathway in skin fibroblasts to induce collagen synthesis, albeit at a later time point 
(12 hours) 45.   Similarly for SFN, we did not observe direct antioxidant activity for API in primary 
chondrocytes though the literature describes varied outcomes and mechanisms for API including 
antioxidant activity that may be cell type dependent. Yokomizo & Moriwaki describe a lack of radical 
scavenging activity for API in Caco-2 cells 46, and API is described as a driver of ROS production 47, 
which we did not observe in chondrocytes (data not shown). Conversely, Crasci et al describe free 
radical scavenging activity for both API and LUT in chondrocytes 48. 
Our data on both metalloproteinase expression and explant cartilage degradation support a recent 
study demonstrating in vivo, the potential for ISO (administered by intraperitoneal injection) to 
protect articular cartilage, where the authors also show protection of subchondral bone tissue in the 
joint of mice 28. This followed another recent report of ISO inhibition of IL-1-induced 
metalloproteinase expression in rats 29. Interestingly and in contrast to SFN and API, ISO showed a 
consistent dose dependent inhibition of tBHP-induced ROS production indicating some direct anti-
oxidant activity.  We did not find evidence to support an interaction of ISO with any of the reporters 
tested and suggest an interaction with Nrf2 to be more likely 30,49,50 . 
LUT showed a similar activity profile to ISO overall despite being structurally more similar to API (one 
hydroxyl group difference in the B ring).  ISO inhibition of tBHP-induced ROS production was striking 
in relation to other activity measures and supports an earlier report in Caco-2 cells 46, where no 
effect by API was also seen.  There are a number of reports of LUT that describe reactive oxygen and 
nitrogen species scavenging, transition metal chelation and antioxidant enzyme induction and is 
reviewed in detail elsewhere 21.  Nonetheless, we observed no marked interaction with the pathway 
reporters excepting the weak interaction with the IL-1/NFκB reporter.  Despite the repression of 
metalloproteinase expression by LUT (also seen by others 22,51) that was borne out in our cartilage 
degradation assay, it was surprising to observe an antagonistic relationship for reducing MMP13 
expression between LUT and each of the remaining bioactives.   
It is possible that the anti-inflammatory/cytoprotective activities of SFN and antioxidant activities of 
ISO culminate in the synergistic interaction to reverse IL-1-induced MMP13 expression that we have 
identified.  The nearly additive relationship of SFN and API could be explained by their similar activity 
profiles, which may saturate signalling pathways, whilst neither having direct antioxidant activities in 
our hands. However, this may be simplistic since the interaction profile of SFN/API with MMP13 
expression differs substantially at different effect levels, being mild to moderately synergistic at 
lower effect levels.  A high effect level, though clinically desirable, is not a necessity in terms of OA 
prevention or treatment.  
Our data suggest antagonistic interactions (i.e. the effect of both compounds is less than the additive 
effect of the individual compounds) between SFN/LUT and ISO/LUT, which are more difficult to 
explain.  Interestingly all combinations with 3 or more bioactives were antagonistic, except for the 
SFN/API/ISO combination, which was only moderately antagonistic, possibly negated by the SFN/ISO 
interaction.  More broadly speaking, food matrices or food-drug interactions present a far more 
complicated milieu.   
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We also assayed the Nrf2-induced HO-1 gene and the NFκB-induced A20 gene, both readouts of key 
pathways in OA, where treatment with both SFN and ISO showed a greater effect than the additive 
effects of the single compounds.  
We have clearly identified dietary-bioactives with the strong potential to be chondroprotective in 
vivo and with SFN and ISO displaying synergy. The concentrations of bioactives in our in vitro assays 
are either equivalent or higher than reported plasma concentrations after consumption (e.g. 52-54.  
However, compounds or their metabolites can accumulate with repeated consumption, or be 
concentrated intracellularly55.  The potential for functional foods or supplementation also increases 
the achievable concentration in vivo.   It is worth noting that dietary compounds undergo extensive 
metabolism following ingestion and even when metabolism is well established, the mix of parent 
compound and metabolites that act upon the articular joint is unknown.  It is also likely that the 
metabolites produced upon ingestion may be more active than the parent compound 56.  The only 
way to understand this is to perform feeding experiments in animal models of disease using 
chemically-defined foods as we have done for SFN alone16.  In vivo experiments also enable a 
comparison of mechanism-of-action with the in vitro and ex vivo analyses.  This is the direction of 
our future research in this area.   
We conclude that diet-derived bioactives may be important modulators of cartilage homeostasis and 
synergistic relationships between bioactives (potentially SFN/ISO) in primary chondrocytes may have 
a role in chondroprotection and counterbalancing inflammation.  
 
Materials and Methods 
Materials 
SFN was from Toronto Research chemicals, CAN. All other bioactives were obtained from Stratech, 
UK.  All cytokines were obtained from Firstlink Ltd (UK) except Wingless-Type MMTV Integration Site 
Family 3A (WNT3A), which was obtained from R&D Systems.  The Proteome Profiler Array (cat: 
ARY003B) was obtained from R&D Systems, UK.  
Methods 
A flow diagram to summarise the experimental process is shown in Supplementary Information. 
Cell culture and treatments 
The human chondrosarcoma SW1353 cell line was purchased from ATCC and the C28/I2 cell line was 
a kind gift from Mary Goldring, HSS Research Institute (USA).  Primary chondrocytes were obtained 
as described previously 16. All experimental protocols were approved by NRES Committee East of 
England (ref: 08/h0304/85+5).  All tissue donors gave informed written consent. All methods were 
performed in accordance with relevant laboratory guidelines and institutional regulations.  All 
treatments included 30 min pre-incubation with bioactive compound followed by cytokine 
treatment.  Cells were propagated in in Dulbecco’s modified Eagles medium (DMEM, GlutaMAX) 
with 10% v/v foetal calf serum and 1000IU/penicillin, 100µg/ml streptomycin, at 37°C, 5% CO2. 
Complementary DNA (cDNA) synthesis and quantitative reverse transcription–polymerase chain 
reaction (qRT-PCR).  
Whole cell lysates were harvested with Cells-to-cDNA II Cell Lysis Buffer (Ambion). Lysates were 
treated with DNase I (Ambion) and reverse transcribed in a total volume of 20 µl, using 200 ng 
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random primers and 100 units Moloney murine leukaemia virus reverse transcriptase (Invitrogen), 
according to the manufacturer’s instructions, in the presence of 40 units RNasin (Promega). Relative 
quantification of genes was performed using an ABI Prism 7500 Sequence Detection System (Applied 
Biosystems). PCRs used 5 µl of reverse-transcribed RNA (a 10-fold dilution of cDNA was used for 18S 
analyses). The MMP and ADAMTS primers and probes were previously described 57,58. The primers 
and probes for HO-1, A20 were designed using the Universal Probe Library (Roche). Gene expression 
was normalised to ribosomal 18S and relative quantification was calculated using 2^-ΔCt. 
Gene promoter reporter assays.  
SW1353 cells were plated at 6x103 cells/well in 96-well plates and left to adhere overnight.  At least 
three independent experiments were carried out each performed in triplicate (n=3).  Transfections 
were carried out using 150 ng reporter plasmid DNA and 50ng renilla control plasmid and 
Lipofectamine 2000 (Fisher Scientific) for 24 hours. Cells were synchronised by serum starvation 
overnight, prior to treatments.  Optimal time and cytokine concentrations were determined for each 
reporter individually and used in all downstream experiments. Cytokine treatments were: 
interleukin-1 (IL1) (5ng/ml) 2 hours; transforming growth factor beta (TGFβ) (1ng/ml), 6 hours; bone 
morphogenic protein 6 (BMP6) (200ng/ml), 24 hours; wingless-type MMTV integration site family 3A 
(WNT3a) (100ng/ml), 24 hours.  Luminescence was measured using the Dual-Glo® Luciferase Assay 
System (Promega) and EnVision Multilabel Plate Reader (PerkinElmer). pGL3 BRE Luciferase was a 
gift from Martine Roussel & Peter ten Dijke (Addgene plasmid # 45126)59, pGL4.32[luc2P/NFκB-
RE/Hygro] (Promega), pGL3[CAGA-luc] was a kind gift from Jean-Michel Gauthier60, M50 Super 8x 
TOPFlash was a gift from Randall Moon (Addgene plasmid # 12456)61. 
Reactive Oxygen Species (ROS) Analysis 
ROS were detected using 2’,7’– dichlorofluorescin diacetate (DCFDA Cellular ROS Detection Assay Kit 
from Abcam (cat: ab113851)) according to the manufacturer’s instructions. Briefly, primary 
chondrocytes were plated at 8x103 cells per well in 96-well plates.  The experiment was repeated 
three times using three different patient cell isolates (n=3), each performed in triplicate.  Treatments 
were 1.5-12 µM SFN, API, ISO or LUT pre-treatment for 30 mins ± (100 µM) tert-Butyl hydroperoxide 
(tBHP) for 4 hours.  ROS levels were measured at Ex/Em 492/530nm using EnVision Multilabel Plate 
Reader (PerkinElmer). 
In vitro cartilage degradation assays 
Cartilage explants were pre-treated with 0-24 µM SFN, API, ISO or LUT.  Cytokines IL-1 and OSM (0.5 
ng/ml and 5 ng/ml respectively) were added to induce cartilage breakdown.  All treatments were 
performed in triplicate and the experiment performed three times (n=3).  Remaining cartilage was 
papain-digested overnight at 65°C.  Glycosaminoglycan (GAG) was measured in the media and 
digested cartilage as described previously 62,63. 
Kinase signalling pathway analysis 
Primary chondrocytes were plated at 3x106 cells per well in 150 mm plates and allowed to adhere 
overnight.  Chondrocytes were treated with IL-1β (5ng/ml), for 10 mins with or without SFN, API or 
ISO (10µM) pre-treatment (30 mins).  Cell lysates were prepared and applied to Proteome Profiler 
Array (R & D Systems) according to the manufacturer’s instructions.  Phosphorylation levels were 
semi-quantified using ImageJ software. 
Cytotoxicity in HACs 
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HACs were treated with 10 µM of each bioactive for 24 hours in three independent cell isolates 
(n=3).  Lactate dehydrogenase (LDH) was measured in the culture media using the CytoTox 96® 
NonRadioactive Cytotoxicity Assay (Promega) according to the manufacturer’s instructions.  Total 
LDH was measured by lysing cells.  Absorbance was measured at 492nm using an EnVision Multilabel 
Plate Reader (PerkinElmer) (Supplementary data S4). 
Data availability 
The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
Statistical testing 
Fold change values were log transformed and one-way analysis of variance (ANOVA) with Dunnett’s 
post-test, were performed using GraphPad Prism version 7.03 for Windows to obtain adjusted p-
values.  Mean fold change and confidence intervals are reported for fold change values.   p<0.05 was 
considered significant.  Synergism was analysed using the Chou & Talalay method 64 and CompuSyn 
v1.0 software. http://www.combosyn.com/index.html 
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Figure Legends 
Figure 1.  IL-1-induced MMP13 gene expression in human primary articular chondrocytes.  Four 
selected bioactives (a) sulforaphane (SFN), (b) apigenin (API), (c) isoliquiritigenin (ISO), (d) luteolin 
(LUT) were titrated against IL-1 treatment (5ng/ml) in at least three independent isolates of human 
primary articular chondrocytes (n=3) each performed in triplicate, for 6 h to establish a dose 
response.  MMP13 mRNA expression was measured using RT-qPCR and normalised to 18S.  Data is 
expressed as mean fold change (FC) ±SEM. One-way ANOVA, and all treatments were compared to 
IL-1 treatment with Dunnett’s post-test. Statistical significance is shown as p<0.05 *, p<0.01 **, 
p<0.001 ***p=0.0001**** 
Figure 2.  Reactive oxygen species (ROS) measured using the DCFDA assay in human primary 
articular chondrocytes.  Cells were treated with 100 µM tert-butyl-hydroperoxide (tBHP) alone (4 h) 
± pre-treatment with (a) SFN, (b) API, (c) ISO or (d) LUT at 0.75-12 µM for 30 mins.  Data are from 
three independent isolates of human primary articular chondrocytes (n=3), where each experiment 
was performed in triplicate. Data are shown as mean fold change (FC) to control ± SEM. One-way 
ANOVA, and all treatments were compared to IL-1 treatment with Dunnett’s post-test.  Statistical 
significance is shown as: p<0.01 **, <0.001***, p≤0.0001****  
Figure 3.  Transcriptional signalling pathway analysis.  Luciferase reporter activity for IL-1/nuclear 
factor-kappa B, TGF-β/Smad2/3, BMP6/Smad1/5/8 and Wnt3A/TCF/Lef (TOPFlash), and using the 
SW1353 chondrosarcoma cell line in response to (a-d) SFN, (e-h) API, (i-l) ISO or (m-p) LUT 
treatment.  Cells were treated with IL-1 (5ng/ml, 2 h), TGF-β (1ng/ml, 6 h), BMP6 (200ng/ml, 24 h) 
and Wnt3a (100ng/ml, 24 h).  Values given are from at least three independent experiments (n=3) 
where each experiment was performed in triplicate.  Data are shown as mean fold change (FC) to 
control ± SEM. One-way ANOVA, and all treatments were compared to IL-1 treatment with 
Dunnett’s post-test.  Statistical significance is shown as: p<0.05 *, p<0.01 **, p<0.001***, p≤0.0001. 
RLU – relative light units (normalised to control plasmid). 
Figure 4.  Cartilage tissue degradation in vitro.  Aggrecan loss measured using 1,9-dimethyl-
methylene blue assay from bovine cartilage explants in response to (a) SFN, (b) API, (c) ISO or (d) LUT 
treatment (open bars), + IL-1/OSM at 0.5ng/ml and 5ng/ml respectively (black bars).  Values given 
are from three independent experiments (n=3) and each performed in triplicate.  Data are shown as 
mean percent loss of total glycosaminoglycan (GAG) ± SEM. One-way ANOVA, and all treatments 
with cytokines were compared to IL-1/OSM treatment alone with Dunnett’s post-test.  Statistical 
significance is shown as: p<0.05* 
Figure 5.  Cytokine-induced expression levels of key genes in osteoarthritis with SFN/ISO 
combination treatment. IL1-induced gene expression of ADAMTS4, ADAMTS5, HO-1 and A20 in 
human articular primary chondrocytes (HACs).  HACs were pre-treated with SFN or ISO individually 
and in the equipotent SFN:ISO combination ratio: 0.75:0.625 µM for 30 mins followed by IL1 
(5ng/ml) 6 hours. Gene expression was measured in at least three independent isolates of human 
primary articular chondrocytes (n=3) by RT-qPCR and normalised to 18S. Data is expressed as mean 
fold change (FC) from IL-1 ±SEM.  One-way ANOVA, and all treatments were compared to IL-1 
treatment with Dunnett’s post-test. Statistical significance is shown as: p<0.05 *, p<0.01 **, 
p<0.001***, p≤0.0001****. 
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Tables 
 
Induced MMP1 MMP13 ADAMTS4 ADAMTS5
Bioactive Mean FC (95% CI) 
p-
value 
Mean FC 
(95% CI) 
p-
value 
Mean FC 
(95% CI) 
p-
value 
Mean FC 
(95% CI) 
p-
value 
Genistin 0.75 (-0.88 to 1.39) 
0.994 0.89 (-0.62 
to 0.84) 
0.999 0.81 (-0.50 
to 0.88) 
0.997 0.77 (-0.62 
to 1.07) 
0.996
Luteolin 0.30 (-0.43 to 1.84) 
0.429 0.39 (-0.12 
to 1.34) 
0.201 0.41 (-0.10 
to 1.28) 
0.068 0.27 (-0.11 
to 1.58) 
0.075
Polydatin 0.73 (-0.86 to 1.41) 
0.997 0.74 (-0.47 
to 0.99) 
0.987 0.80 (-0.49 
to 0.89) 
0.997 0.84 (-0.68 
to 1.01) 
0.999
Curcumin 0.61 (-0.74 to 1.53) 
0.899 0.62 (-0.35 
to 1.11) 
0.799 0.83 (-0.52 
to 0.86) 
0.992 0.44 (-0.28 
to 1.41) 
0.124
Apigenin 0.23 (-0.36 to 1.91) 
0.186 0.18 (0.09 
to 1.55) 
0.005 0.11 (0.20 
to 1.58) 
0.0001 0.22 (-0.06 
to 1.62) 
0.018
Myricetin 0.97 (-1.10 to 1.16) 
0.999 1.07 (-0.80 
to 0.66) 
0.999 1.34 (-1.03 
to 0.35) 
0.994 0.77  (-0.61 
to 1.07) 
0.991
Isoliqu 0.23 (-0.36 to 1.90) 
0.151 0.14 (0.14 
to 1.59) 
0.0005 0.08 (0.15 
to 1.69) 
0.0001 0.11 (0.05 to 
1.73) 
0.001
Ursolic acid 0.82 (-0.95 to 1.32) 
0.991 0.31 (-0.03 
to 1.43) 
0.041 0.69 (-0.38 
to 1.00) 
0.902 0.33 (-0.17 
to 1.52) 
0.136
EGCG 1.03 (-1.16 to 1.11) 
0.999 1.01 (-0.74 
to 0.72) 
0.999 1.27 (-0.95 
to 0.42) 
0.999 0.97 (-0.81 
to 0.88) 
0.999
Naringin 0.94 (-1.07 to 1.20) 
0.999 1.13 (-0.86 
to 0.60) 
0.999 1.16 (-0.85 
to 0.53) 
0.999 0.97 (-0.81 
to 0.87) 
0.999
Sulforaphane 0.17 (-0.31 to 1.96) 
0.163 0.12 (0.15 
to 1.61) 
0.001 0.03 (0.28 
to 1.66) 
0.0001 0.23 (-0.07 
to 1.61) 
0.053
 
Table 1.  Inhibition of cytokine-induced levels of key osteoarthritis matrix metalloproteinase 
mRNA expression in primary chondrocytes.  Cytokine-induced matrix metalloproteinase gene 
expression in human articular primary chondrocytes pre-treated with 10µM of each bioactive 30 
mins then 5ng/ml interleukin-1 (IL-1) for 6 hours. Cell isolates from three patients (n=3) were used 
and each independent experiment performed in triplicate.  Levels of MMP1, MMP13, ADAMTS4 and 
ADAMTS5 mRNA, normalised to 18S were measured by RT-qPCR. Mean fold change (FC) to IL-1, 95% 
confidence intervals (CI) are shown.  One-way ANOVA, and all treatments were compared to IL-1 
treatment with Dunnett’s post-test corrected p-values shown. 
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Basal MMP1 MMP13 ADAMTS4 ADAMTS5 
Bioactive Mean FC (95% CI) 
p- 
value 
Mean FC 
(95% CI) 
p-
value 
Mean FC 
(95% CI) 
p-
value 
Mean FC  
(95% CI) 
p-
value 
Genistin 1.03 (-2.55 
to 2.50) 
0.999 1.09 (-3.14 
to 2.96) 
0.999 - - 0.96 (-0.48 to 0.56) 
0.999
Luteolin 0.96 (-2.48 
to 2.56) 
0.999 1.83 (-3.88 
to 2.22) 
0.997 - - 0.71 (-0.23 to 0.81) 
0.766
Polydatin 0.90 (-2.42 
to 2.62) 
0.999 1.88 (-3.93 
to 2.16) 
0.985 - - 0.98 (-0.50 to 0.54) 
0.999
Curcumin 1.13 (-2.65 
to 2.39) 
0.999 2.43 (-4.48 
to 1.61) 
0.822 - - 0.70 (-0.22 to 0.83) 
0.838
Apigenin 0.76 (-2.28 
to 2.77) 
0.912 2.05 (-4.10 
to 2.00) 
0.996 - - 0.59 (-0.11 to 0.93) 
0.337
Myricetin 0.74 (-2.26 
to 2.78) 
0.914 1.89 (-3.94 
to 2.16) 
0.999 - - 0.77 (-0.29 to 0.75) 
0.965
Isoliqu 0.95 (-2.47 
to 2.57) 
0.999 2.02 (-4.07 
to 2.02) 
0.991 - - 0.49 (-0.03 to 1.01) 
0.148
Ursolic acid 4.35 (-5.87 
to -0.82) 
0.004 0.64 (-3.04 
to 3.77) 
0.864 - - 0.69 (-0.21 to 0.83) 
0.532
EGCG 1.11 (-2.63 
to 2.41) 
0.999 1.81 (-3.86 
to 2.24) 
0.999 - - 0.62 (-0.14 to 0.90) 
0.442
Naringin 0.95 (-2.48 
to 2.57) 
0.999 1.09 (-3.14 
to 2.95) 
0.999 - - 0.92 (-0.44 to 0.60) 
0.999
Sulforaphane 0.92 (-2.44 
to 2.60) 
0.999 1.75 (-3.80 
to 2.29) 
0.993 - - 0.25 (0.23 to 1.27) 
0.001
 
Table 2.  Inhibition of basal levels of key osteoarthritis matrix metalloproteinase mRNA expression 
in primary chondrocytes.  Basal matrix metalloproteinase gene expression in human articular 
primary chondrocytes pre-treated with 10µM of each bioactive for 6 hours. Cell isolates from three 
patients were used (n=3) and each independent experiment performed in triplicate.  Expression 
levels of MMP1, MMP13, ADAMTS4 and ADAMTS5 mRNA, normalised to 18S were measured by RT-
qPCR. Mean fold change (FC) to control, 95% confidence intervals (CI) are shown. One-way ANOVA, 
and all treatments were compared to control with Dunnett’s post-test corrected p-values shown. 
 
Bioactive Dm m r
SFN 3.33 1.43 0.75 
API 6.76 2.54 0.93
ISO 2.89 1.24 0.73 
LUT 3.80 1.32 0.84 
 
Table 3. Dose-effect relationship parameters of SFN, API, ISO and LUT individually against IL1-
induced MMP13 mRNA expression in primary chondrocytes.  IC50 concentration (Dm) is shown in 
µM.  The slope (m) and linear correlation coefficient (r) of the median-effect plot are given. Values 
are the mean of three human articular primary chondrocyte isolates (n=3) and each experiment 
contained six concentrations for each bioactive, in duplicate. Gene expression was measured using 
RT-qPCR and normalised to 18S. 
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 CI Values  
Bioactive 
Combo 
ED50 ED75 ED90 ED95 mean CI Assigned 
symbol 
SA 0.706 0.879 1.127 1.356 1.017 ±
SI 0.872 0.758 0.661 0.604 0.724 ++ 
SL 1.066 1.404 1.851 2.235 1.639 - - - 
AI 1.213 1.072 0.997 0.975 1.064 ± 
AL 0.887 1.008 1.189 1.361 1.111 -
IL 3.111 2.208 1.569 1.244 2.033 - - - 
SAI 1.066 1.161 1.311 1.454 1.248 - - 
AIL 1.919 1.754 1.663 1.642 1.744 - - - 
ILS 1.550 1.712 1.896 2.034 1.798 - - - 
LSA 1.753 1.836 1.978 2.119 1.922 - - -
SAIL 1.368 1.770 2.357 2.917 2.103 - - - 
 
Table 4. Bioactive combination indices of SFN, API, ISO and LUT for MMP13 expression in primary 
chondrocytes. Combination Index (CI) values of bioactive combinations against IL1-induced MMP13 
mRNA expression in human articular primary chondrocytes (n=3) measured by RT-qPCR and 
normalised to 18S.  Combination ratios were based on IC50 values. Each bioactive component had a 
combination ratio of: S:A:I:L = 0.75:1:0.625:1.25 µM.  Assigned symbols are: nearly additive (±), 
moderate synergism (++), slight antagonism (-), moderate antagonism (- -), antagonism (- - -) 32.  CI = 
Combination index.  
 
 DRI Values at:  CI Values at: 
Combination ED50 ED75 ED90 ED95 ED50 ED75 ED90 ED95
S + 1.418 3.292 7.641 13.549  0.706 0.879 1.127 1.356 
A (0.75:1) 
 
1.891 4.389 10.188 18.066   
S + 1.479 2.930 5.808 9.248  0.872 0.758 0.661 0.604 
I (0.75:0.625) 
 
1.232 2.442 4.840 7.706      
A + 3.328 5.781 10.043 14.622  1.213 1.072 0.997 0.975 
I (1:0.625) 2.080 3.613 6.277 9.139      
 
Table 5. Dose reduction Index (DRI) values for MMP13 expression in relation to combination index 
(CI) values for synergistic combinations of SFN/API, SFN/ISO and API/ISO in primary chondrocytes.  
The DRI describes the fold reduction in bioactive concentration needed in a synergistic combination 
at each effect level shown (compared with each bioactive alone). Gene expression was measured by 
RT-qPCR, normalised to 18S, from three independent experiments, n=3.  Synergism (CI <1), additivity 
(CI =1), antagonism (CI >1).  
 





